Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011

      -- Company reports record product gross profit and significant revenue growth --


      News provided by

      Verenium Corporation

      Nov 10, 2011, 04:00 ET

      Share this article

      Share this article


      SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the third quarter and nine months ended September 30, 2011.

      "We have made strong financial and operational progress in the first nine months of this year," said James E. Levine, President and Chief Executive Officer at Verenium. "In the third quarter of 2010 we shifted our business strategy toward growing a leading, commercial industrial enzymes business.  The continued increase in product revenue and record product gross profit we saw in the third quarter of 2011 are important indicators that we've had a solid year of progress against our new strategy and are well on our way to building a successful industrial biotechnology company."  

      Company Highlights

      Since the beginning of 2011, Verenium has made significant progress on both operational and financial fronts.  Recent accomplishments include:

      Operational/Industry Performance:

      Animal Health and Nutrition

      • Revenue in this product line is flat year-to-date, with improved performance in the third quarter from stronger sales by our marketing partner, Danisco, now part of E. I. du Pont de Nemours and Company; and
      • Announced and continued to progress the strategic collaboration with Novus International Inc. to jointly develop and commercialize a suite of new animal health and nutrition enzyme products from Verenium's late-stage product pipeline.

      Grain Processing

      • Grew 2011 year-to-date revenues from the Company's grain processing enzymes by 29% over the same period in 2010; and
      • Grew grain processing revenue to represent 29% of 2011 year-to-date product revenues, from 26% during the same period in 2010.

      Oilseed Processing

      • Achieved more than 100% increase in 2011 year-to-date revenue from Purifine® PLC over the same period in 2010, resulting from the deployments by Molinos Rio de la Plata and Terminal 6, the world's two largest soybean crushing facilities, both located in Argentina;
      • Oilseed processing has grown to represent 11% of 2011 year-to-date product revenues from 6% during the same period in 2010;
      • Increased implementations of Purifine® PLC to seven plants, with six additional plants in the engineering and construction phase; and
      • Completed first shipment of Purifine® PLC to China.

      Corporate/Financial:

      • Increased total product revenue by 14% to $42.3 million for the nine months ended September 30, 2011, compared to $37.1 million for the same period in 2010;
      • Increased 2011 year-to-date product revenue from Grain and Oilseed Processing and other product lines as a percentage of product revenue to approximately 41% from approximately 34% in the same period in 2010;
      • Increased product gross profit dollars by 37% and 16% for the three and nine months ended September 30, 2011 respectively, when compared to the same periods in 2010;
      • Signed a license agreement granting Biocee access to Verenium's unique desulfurization organisms and technology further validating the strength and applicability of Verenium's technology outside of commercial enzymes;
      • Announced up to $16 million in new secured credit facilities to be used for general working capital purposes;
      • Repurchased $9.3 million in convertible notes principal outstanding, including retiring the outstanding secured 9% convertible notes; and
      • Ended the quarter with unrestricted cash and cash equivalents totaling $35.7 million, $5.0 million in restricted cash and convertible notes outstanding of $34.9 million.

      Financial Results

      In the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued  operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP Biofuels North America LLC.

      Revenues

      Revenues for the periods ended September 30, 2011 and 2010 were as follows (in thousands):



      Three Months Ended 

      September 30,


      Nine Months Ended 

      September 30,


      2011


      2010


      2011


      2010

      Revenues:








            Animal Health and Nutrition

      $          8,624


      $         7,696


      $        24,734


      $        24,537

            Grain Processing

      3,942


      3,364


      12,371


      9,605

            Oilseed Processing

      1,929


      950


      4,541


      2,258

            All other products

      247


      223


      606


      685

                 Total product

      14,742


      12,233


      42,252


      37,085

      Collaborative

      3,674


      339


      4,694


      1,391

      Total revenues

      $         18,416


      $       12,572


      $        46,946


      $        38,476




      Total revenues for the nine months ended September 30, 2011 increased 22% to $46.9 million from $38.5 million for the same period in the prior year, with product revenues representing 90% or greater of total revenues in both periods. Product revenues for the nine months ended September 30, 2011 increased 14% to $42.3 million from $37.1 million for the same period in the prior year, primarily due to an increase in revenues from grain processing enzymes, including Fuelzyme® alpha-amylase, and Deltazym® GA L-E5 glucoamylase. These products continued to gain traction in the grain ethanol markets and together with Purifine® PLC for soybean oil processing, achieved significant revenue growth over 2010.

      During the third quarter of 2011, in conjunction with rights assigned to Verenium as part of the separation agreement with Syngenta Participations AG in 2009, the Company received a license fee of $3.25 million for a commercial enzyme candidate that Syngenta had previously licensed to a third party.  This amount was received by the Company and recorded into collaborative revenue for the three and nine months ended September 30, 2011 and represented non-recurring revenue.

      Product Gross Profit and Gross Margin

      Product gross profit for the nine months ended September 30, 2011 increased 16% to $16.1 million from $13.9 million for the same period in prior year. Gross margin increased to 38% of product revenue for the nine months ended September 30, 2011, compared to 37% for the nine months ended September 30, 2010.  Gross margin increased primarily due to the overall growth and improvement from our grain and oilseed processing products.  The Company achieved a record $6.0 million in product gross profit during the three months ended September 30, 2011.

      Operating Expenses (excluding cost of product revenue and restructuring expense)

      Excluding cost of product revenues and restructuring, total operating expenses related to continuing operations for the nine months ended September 30, 2011 decreased to $21.7 million (including share-based compensation of $0.5 million) from $25.1 million  (including share-based compensation of $0.8 million) for the same period in the prior year; primarily due to a reimbursement of legal fees of $1.1 million for expenses incurred during 2010, reduction of facilities related costs as a result of BP assuming the Company's San Diego building leases, and to initiatives to decrease general and administrative expenses. Additionally, during the third quarter of 2010, the Company paid and expensed bonus payments of $1.4 million. As a partial offset, research and development costs for continued investment in pipeline products showed an increase.  

      Restructuring Expense

      On March 31, 2011 the Company closed its office in Cambridge, Massachusetts, resulting in a charge of $2.9 million, consisting of employee termination costs, facilities closure costs, and employee relocation costs for several employees who were relocated to San Diego.

      Operating Loss from Continuing Operations

      Operating loss from continuing operations for the nine months ended September 30, 2011 was $3.9 million compared to $9.8 million for the same period in 2010.  Excluding the impact of restructuring expenses of $2.9 million, operating loss from continuing operations decreased to $0.9 million, primarily due to the reimbursement of legal fees, the $1.4 million bonus paid and expensed during the third quarter of 2010, and further reductions in general and administrative expenses.

      Net Income (loss) from Continuing Operations

      Net income from continuing operations for the nine months ended September 30, 2011 was $8.1 million compared to a net loss of $11.9 million for the same period in 2010, on a GAAP accounting basis. Adjusted for the impact of non-cash items related to the Company's convertible debt and non-cash income tax benefit in 2010, the Company's non-GAAP pro-forma net loss from continuing operations for the nine months ended September 30, 2011 was $6.2 million compared to $16.0 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

      Balance Sheet

      The Company ended the third quarter of 2011 with $35.7 million in cash and cash equivalents, $5.0 million in restricted cash, and $34.9 million in debt at face value.

      "We ended the third quarter with strong top and bottom line performance, as well as record product gross profit," said Jeffrey Black, Senior Vice President and Chief Financial Officer.  "We believe we have balanced the right level of investment with appropriate cost controls, and remain focused on continued growth and medium-term profitability."

      About Verenium

      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, ability to obtain additional capital to support its planned operations and financial obligations, dependence on patents and proprietary rights, and protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Kelly Lindenboom

      Vice President, Corporate Communications

      858-431-8580

      [email protected]

      Sarah Carmody

      Manager, Corporate Communications

      858-431-8581

      [email protected]




      Verenium Corporation

      Condensed Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2011


      2010


      2011


      2010

      Revenues:








        Product

      $     14,742


      $    12,233


      $    42,252


      $     37,085

        Collaborative and license

      3,674


      339


      4,694


      1,391

      Total revenue

      18,416


      12,572


      46,946


      38,476









      Operating expenses:








        Cost of product revenue

      8,698


      7,833


      26,174


      23,179

           Product gross profit

      6,044


      4,400


      16,078


      13,906

           Product gross margin

      41%


      36%


      38%


      37%

        Research and development

      2,673


      1,448


      7,593


      4,124

        Selling, general and administrative

      4,940


      7,838


      14,106


      21,010

        Restructuring charges

      20


      --


      2,940


      --

      Total operating expenses

      16,331


      17,119


      50,813


      48,313









      Operating income (loss) from continuing operations

      2,085


      (4,547)


      (3,867)


      (9,837)









      Other income and expense:








        Interest and other expense, net

      (618)


      (2,072)


      (2,371)


      (6,179)

        Gain on debt extinguishment upon conversion of convertible notes

      --


      --


      --


      598

        Gain (loss) on debt extinguishment upon repurchase of convertible notes

      4,065


      (3,384)


      15,349


      (3,384)

        Gain (loss) on net change in fair value of derivative assets and liabilities

      290


      (299)


      (1,005)


      (1,017)

      Total other income (expense), net

      3,737


      (5,755)


      11,973


      (9,982)









      Net income (loss) from continuing operations before income taxes

      5,822


      (10,302)


      8,106


      (19,819)

      Income tax benefit

      --


      7,928


      --


      7,928

      Net income (loss) from continuing operations

      5,822


      (2,374)


      8,106


      (11,891)









      Net Income (loss) from discontinued operations

      (24)


      31,980


      37


      9,841

      Less: Loss attributed to noncontrolling interests in

        consolidated entities – discontinued operations

      --


      10,108


      --


      25,283

      Net income attributed to Verenium

      $       5,798


      $   39,714


      $      8,143


      $     23,233

      Basic and diluted net income (loss) per share:

        Continuing operations

      $         0.46


      $     (0.19)


      $        0.64


      $       (0.97)

        Discontinued operations

      $              --


      $       2.59


      $           --


      $         0.80

        Net income

      $         0.46


      $       3.21


      $        0.65


      $         1.90

      Shares used in computing basic and diluted net income (loss) per share

      12,607


      12,371


      12,607


      12,231





      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (unaudited, in thousands)



      September 30,


      December 31,


      2011


      2010





      Cash and cash equivalents

      $          35,672


      $            87,929

      Restricted cash, short term

      5,000


      --

      Accounts receivable, net

      7,981


      6,708

      Inventory, net

      5,948


      5,316





      Other current assets  

      2,715


      2,694

      Restricted cash, long term

      --


      5,000

      Property and equipment, net  

      5,513


      3,134

      Other noncurrent assets  

      463


      976

      Total assets  

      $           63,292


      $         111,757









      Current liabilities, excluding deferred revenue,

        restructuring, convertible notes and liabilities of

        discontinued operations

      $           10,138


      $           16,849

      Deferred revenue, current  

      3,894


      894

      Accrued restructuring, current

      587


      --

      Convertible notes, at carrying value (face value of

        $34.9 million at September 30, 2011 and

        $74.7 million at December 31, 2010)

      34,851


      88,011

      Other long term liabilities  

      980


      1,216

      Liabilities of discontinued operations  

      523


      1,617

      Stockholders' equity  

      12,319


      3,170

      Total liabilities and

         stockholders' equity  

      $          63,292


      $         111,757








      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)

      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three and nine months periods ended September 30, 2011 and 2010, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.


      Non-GAAP Pro Forma Net Loss From Continuing Operations


      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2011


      2010


      2011


      2010

























      Income (loss) from continuing operations

      $        5,822


      $        (2,374)


      $         8,106


      $      (11,891)









      Adjustments:  








      Income tax benefit

      --


      (7,928)


      --


      (7,928)

      (Gain) loss on debt extinguishment upon repurchase of convertible notes

      (4,065)


      3,384


      (15,349)


      3,384

      (Gain) on debt extinguishment upon conversion of convertible notes

      --


      --


      --


      (598)

      (Gain) loss on net change in fair value of derivative assets and liabilities

      (290)


      299


      1,005


      1,017

      Non-GAAP pro forma net income (loss) from continuing operations  

      $        1,467


      $        (6,619)


      $        (6,238)


      $      (16,016)

      Non-GAAP pro forma net income (loss) from continuing operations per share  

      $           0.12


      $            (0.54)


      $          (0.49)


      $          (1.31)












      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.